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Background:Newbiomarkers are needed to identify the stage of hepatitis C virus (HCV)-infected diseases in order to
reduce the mortality rates. Herein, we investigated whether serum 3β-hydroxysterol Δ24-reductase antibody
(DHCR24 Ab) may serve as a prognostic marker for hepatitis C infection progression to hepatocellular carcinoma
(HCC).
Methods: Serum DHCR24 Abs from 395 HCV-positive patients, including 133 chronic hepatitis (CHC), 85 liver
cirrhosis (LCC), and 177 HCC (HCC-C) patients; 232 hepatitis B virus (HBV)-positive patients, including 103 chronic
hepatitis (CHB), 56 liver cirrhosis (LCB), and 73 HCC (HCC-B) patients; and 24 healthy controls, were measured
using enzyme-linked immunosorbent assay.
Results: The serumDHCR24 Ab levels were signiﬁcantly higher in patients with CHC than in healthy controls, in LCC
than in CHC, and in LCC than inHCC-C (P b 0.0001 for all). The concentration of serumDHCR24Ab inHCC-B patients
showed no signiﬁcant difference compared to CHB and LCB patients (P= 0.1247). The DHCR24 Ab levels were sig-
niﬁcantly higher in early HCC-C than CHC or LCC patients and in late HCC-C compared to early HCC-C patients. The
sensitivity of the DHCR24 Ab for HCC-C detection (70.6%) was higher than that of alpha-fetoprotein (AFP; 54.8%)
and protein induced by vitamin K absence or antagonist-II (PIVKA-II; 42 · 5%). Moreover, DHCR24 was up-
regulated in HCV-positive, but not HBV-positive tissues or HBV-negative, HCV-negative HCC specimens.
Conclusions:DHCR24 auto-antibody represents a potential noninvasive biomarker for HCV-related liver disease and
may facilitate the diagnosis of PIVKA-II and AFP-negative HCC.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis C virus (HCV) infection has a high prevalence, incidence,
and pathogenicity, and may evolve into cirrhosis and hepatocellular
carcinoma (HCC) (Castello et al., 2010). HCV infection is considered a




. This is an open access article underquasi-species generated from high rates of replication errors (Farazi
andDePinho, 2006). SinceHCVdoes not integrate into the host genome,
HCV-relatedHCC (HCC-C) ismainly induced through indirect pathways,
including chronic inﬂammation, cirrhosis, cell death, and proliferation
(Lorusso and Ruegg, 2008). A hallmark of HCV infection is perturbed
lipid metabolism; HCV exploits host lipids for replication and further
infection. The 3β-hydroxysterol Δ24-reductase (DHCR24) protein
catalyzes the conversion of desmosterol to cholesterol; Bae and Paik,
1997 this reaction appears to be remarkable in HCV infection (Schaefer
and Chung, 2013). Previously, we found that HCV up-regulated DHCR24
expression in human hepatoblastoma-derived RzM6-LC cells and that
DHCR24 overexpression impaired p53 activity by suppressing acetylation
and increasing interactions with theMDM2 proto-oncogene. In turn, this
suppressed the hydrogen peroxide-induced apoptotic response inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
605S. Ezzikouri et al. / EBioMedicine 2 (2015) 604–612hepatocytes (Nishimura et al., 2009; Tsukiyama-Kohara, 2012; Saito et al.,
2012).
The development of novel biomarkers and surveillance strategies in
high-risk populations will permit earlier discovery of HCC and improve
the survival outcomes. Currently, the most commonly used biomarker
for early-stage HCC is alpha-fetoprotein (AFP) (Zhang et al., 2004).
However, the AFP levels remain normal in 15–20% of advanced-stage
HCC patients, and only 10–20% of early-stage HCC patients show
abnormal AFP values (Monsour et al., 2013). Therefore, additional HCC
biomarkers, including protein induced by vitamin K absence or
antagonist-II (PIVKA-II; des-gamma-carboxy-prothrombin), have been
developed (Makuuchi et al., 2008). Nonetheless, the need for novel
biomarkers for early detection of HCC remains an important issue.
Moreover, no biomarker corresponding to the disease progression of
HCV-infected diseases, such as chronic hepatitis, cirrhosis, and HCC,
has been established. Accordingly, this study aimed to evaluate the
levels of serum DHCR24 auto-antibody (DHCR24 Ab) in a broad
spectrum of chronic hepatitis diseases.
2. Materials and Methods
2.1. Subjects
The subjects were prospectively enrolled at the Tokyo Metropolitan
Komagome Hospital, Showa University Fujigaoka Hospital, and Kanaza-
wa University Hospital, Japan. This study was approved by the ethics
committee of each hospital and conducted in accordance with the
Helsinki Declaration. All patients provided informed consent.
Frozen liver samples (cancerous and noncancerous) were obtained
from ﬁve HCC-HCV, ﬁve HCC-HBV and ﬁve HCC-nonBnonC (NBNC)
patients that were obtained from 15 HCC patients at the Liver Unit of
the TokyoMetropolitan KomagomeHospital, Japan and used forWestern
blotting and immunohistochemistry.
Six hundred ﬁfty-one serum samples, collected from September
2007 to November 2014, were obtained from 395 HCV-positive
patients, including 133 moderate chronic hepatitis C (CHC), 85 liver
cirrhosis (LCC), and 177 HCC (HCC-C) patients; 232 HBV patients,
including 103 chronic HBV (CHB), 56 liver cirrhosis (LCB), and 73 HCC
(HCC-B) patients; and 24 healthy controls (Table 1).
Chronic HCV infectionwas deﬁned as detectable serumanti-HCV an-
tibodies and HCV RNA. Liver cirrhosis was by presence of ascites and/or
gastroesophageal varices and deﬁned by the aspartate transaminase
(AST) to platelet ratio index (APRI) and Fibrosis-4 index. APRI (cutoff
value ≧1.00, sensitivity 89%, speciﬁcity 74%, PPV38%, NPV 98%) was cal-
culated as follows: (AST [IU / L] / upper normal limit) × 100/platelets
(109/L) (Wai et al., 2003). The Fibrosis-4 index (cutoff value ≧1.45,
sensitivity 70%, speciﬁcity 74%, PPV42%, NPV 90%) was calculated by:
age (years) × AST (IU / L) / (platelets [109/L] × [alanine aminotransfer-
ase (ALT; IU/L)]½) (Sterling et al., 2006). HCCwas diagnosed by ultraso-
nography and computed tomography and conﬁrmed by liver biopsy,Table 1
Baseline demographic and disease characteristics.
Healthy controls (N = 24)
Mean age ± SD, years 45.08 ± 16.84
Gender (male/female) 9/15
ALT (IU/L), mean ± SD 21.50 ± 10.10
AST (IU/L), mean ± SD 21.92 ± 6.47
AFP (ng/mL), mean ± SD 4.50 ± 3.23
PIVKA-II (mIU/mL), mean ± SD –
Clinical status
Moderate chronic hepatitis (n) –
Liver cirrhosis (n) –
HCC (n) –
Abbreviations: SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotran
onist-II; HCC, hepatocellular carcinoma.and classiﬁed into early and late HCCs according to the pathological
criteria of the international consensus group for hepatocellular neopla-
sia. Early-stage HCC was deﬁned as a single lesion between 2 and 5 cm,
or less than or equal to three lesions each ≤3 cm. Late-stageHCCwas de-
ﬁned by a single lesion N5 cm, or greater than three lesions
(International Consensus Group for Hepatocellular Neoplasia and The
International Consensus Group for Hepatocellular N, 2009).
The diagnosis of chronic HBV infection was conﬁrmed by the pres-
ence of HBV surface antigen in the blood for greater than six months,
HBV core antibodies, and HBV-DNA detection by real-time polymerase
chain reaction. The healthy controls had no medical history of liver
disease, were negative for viral hepatitis markers, and had normal ALT
and AST levels. Table 1 summarizes the main characteristics of the
study patients.
2.2. Western Blotting
Fifteen frozen liver tissue specimenswere homogenized on ice using
a type-A glass homogenizer (Wheaton Science Products, Millville, NJ,
USA) in RIPA buffer (1% sodium dodecyl sulfate, 0.5% NP40, 0.15 M
NaCl, 10 mM Tris pH 7 · 4, 5 mM ethylenediaminetetraacetic acid
[EDTA], and 1 mM dithiothreitol). Proteins were transferred to
Immobilon P polyvinylidene ﬂuoride membranes (Merck Millipore,
Jaffrey, NH,USA). After blockingwith 5%BlockAce™ powder (Dainippon
Pharmaceutical Co., Osaka, Japan) in TBST (0.1% Tween 20, 20 mM
Tris-Cl pH 7.6, and 137 mM NaCl) at room temperature for 2 h, the
membranes were incubated for 2 h with 1-μg/mL of primary antibody
in TBST containing 1% Block Ace. After washing, the membranes were
incubated with 1:2000 horseradish peroxidase-conjugated rabbit anti-
mouse antibody (Dako, Glostrup, Denmark) in TBST containing 1%
Block Ace. Western blotting was performed using DHCR24 monoclonal
antibody (MoAb) 2-152a6 as the primary antibody. Actin (polyclonal
antibody; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used for
normalization.
2.3. Immunohistochemistry of Liver Tissues
Frozen sections of cancerous and noncancerous liver tissues from
HCC patients were prepared in optimal cutting temperature compound
(Ted Pella Inc., Redding, CA, USA), placed on glass slides, thawed,
washed with phosphate-buffered saline (PBS), and ﬁxed with 1% para-
formaldehyde for 10min in PBS. After blocking for 1 hwith PBS contain-
ing 1% bovine serum albumin and 1 mM EDTA, the slides were washed
with PBS and incubated overnight at 4 °C with the primary monoclonal
Abs (5 μg/mL). Next, the slides were washed with PBS thrice and incu-
bated for 30 min with 1:1000 Alexa 488-conjugated goat anti-mouse
immunoglobulin G (IgG) (Fab′)2 fragment or Alexa 568-conjugated
goat anti-rabbit IgG (Fab′)2 fragment (Molecular Probes, Eugene, OR,
USA) in PBS containing 0.05% Tween-20. Subsequently, the slides were
washed thrice with PBS and cover-slipped using Vector-shield (VectorHepatitis C virus group (N = 395) Hepatitis B virus group (N = 232)
68.32 ± 11.40 58.31 ± 12.90
185/210 151/81
54.55 ± 44.80 63.01 ± 159
58.32 ± 36.70 79.25 ± 450
233.31 ± 18823 1850 ± 180900
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Fig. 1. Study proﬁle.
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(Molecular Probes). The slides were observed using conventional
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Fig. 2. Standard concentration curve (OD450) for DHCR24 Ab. (A) Fluorescence-activated cell so
HuH-7 cells and is not secreted. (B) Procedure for puriﬁcation of DHCR24 protein using a DHCR2
from HuH-7 cells by Western blotting (arrow). The left lane contains a molecular weight mark2.4. Puriﬁcation of DHCR24 Protein
DHCR24 protein was puriﬁed from HuH-7 hepatocellular carcinoma






















rting analysis of DHCR24 expression in HuH-7 cells. DHCR24 is expressed on the surface of
4monoclonal Ab (MoAb) 2-152a column. (C) Characterization of DHCR24 protein puriﬁed
er. (D) Reactivity of MoAb 2-152a with puriﬁed DHCR24 antigen from HuH-7 cells.
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dithiothreitol, and 1 mM diisopropylﬂuorophosphate), sonicated, and
centrifuged at 20,400 g for 30 min. The supernatant was incubated at
4 °C for 4 h with 500 μg of DHCR24 MoAb 2-152a IgG immobilized
on a HiTrap N-hydroxysuccinimide-activated high-performance
column (Amersham Bioscience, Amersham, UK) according to the
manufacturer's protocol. The resin was washed with buffer C, and
bound proteins were eluted with 0.2 M sodium bicarbonate (pH 8 · 3)
containing 0.5 M NaCl, and immediately neutralized with an equal
amount of ice-cold 1 M Tris pH 8 · 5.2.5. Enzyme-linked Immunosorbent Assay (ELISA)
ELISAwas performed in ﬂat-bottompolystyrene plates (Greiner Bio-
One GmbH, Frickenhausen, Germany) precoated with 50 μl of puriﬁed
antigen diluted to 5 μg/mL in 0.05 M sodium carbonate Na2CO3 pH 9.0,
overnight at 4 °C. Next, the plates were washed with PBS 0.1% Tween
20 and incubated in blocking buffer (1% Block Ace/PBS-0.1% Tween
20) at 37 °C for 1–2 h. Afterwashing, the samples (dilutedwith blocking
buffer to 1:100), positive controls (mouse polyclonal anti-DHCR24 sera
diluted to 0.5, 1, and 2 μg/mL), and blanks (assayswithout sample)were
added and the plates were incubated at 37 °C for 1–2 h, followed by
washing. Subsequently, the secondary Abs (1:1000; peroxidase
conjugate polyclonal rabbit anti-human IgG [Dako] for samples, and per-
oxidase conjugate polyclonal rabbit anti-Mouse IgG [Dako] for positive
controls) were added and incubated at 37 °C for 1 h. Finally, the plates(A) Komagome Hospital 
(C) Total 
Fig. 3. Serum DHCR24 Ab relative concentrations in hepatitis C virus (HCV)-infected patients w
Serum levels ofDHCR24Ab inhepatitis C patients and healthy controls in (A) Komagomehospit
and healthy controls (all hospitals). Black horizontal lines indicate means, and the error bars in
with HCV infection; HCC-C, hepatocellular carcinoma with HCV infection.were washed to remove the secondary Abs, tetramethylbenzidine/
H2O2-TMB (Bio-Rad, Hercules, CA, USA) was added, and the plates were
incubated at 37 °C for 30 min. The reaction was stopped with 1 N of
H2SO4. The absorbance valueswere readusing a plate spectrophotometer
(Thermo Fisher Scientiﬁc, Waltham, MA, USA) at 450 nm. The assay was
done in blind and interpreted by tree researchers. In addition, the assay
was repeated for approximately 3% of the total samples, and no discrep-
ancy was observed.2.6. Statistical Analysis
Descriptive data are presented as numbers and mean ± SD, as
appropriate. Differences in continuous variables were compared using
the Student's t-test, Mann–Whitney U test, and one-way analysis of
variance (ANOVA). For categorical variables, the Chi-square test was
used. All P-values were two-sided and P b 0.05 was considered signiﬁ-
cant. The area under the receiver operating characteristic curves (AUC
of ROC) and their 95% conﬁdence intervals (CIs), were used to evaluate
the diagnostic value of the DHCR24 Ab and to test the hypothesis that
the AUC is 0.5. Additionally, positive and negative predictive values
and their 95% conﬁdence intervals were calculated. All correlations
were assessed using Spearman's correlation test. The survival rates
were estimated using Kaplan–Meier curves and compared using
two-sided log-rank tests. All statistical analyses were performed using
GraphPad PRISM version 6.0e (GraphPad Software, San Diego, CA,
USA) or MedCalc statistical software.(B) Kanazawa Hospital 
ith chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, and in healthy controls.
al, (B) Kanazawahospital, and (C) Plotted serum levels of DHCR24Ab inhepatitis C patients
dicate the standard deviations. CHC, chronic hepatitis C virus infection; LCC, liver cirrhosis
Table 2
Assessment of the diagnostic accuracy of DHCR24 Ab in HCV-related HCC.
HCC-C vs. healthy HCC-C vs. CHC HCC-C vs. LCC
Sensitivity (%), (95% CI) 70.06 (62.73–76.70) 70.06 (62.73–76.70) 70.06 (62.73–76.70)
Speciﬁcity (%), (95% CI) 100 (85.62–100) 84.21 (76.88–89.95) 42.35 (31.70–53.55)
Positive likelihood ratio 50.44 4.44 1.22
Negative likelihood ratio 0.30 0.36 0.71
Positive predictive value (%), (95% CI) 100 (97.04–100) 94.66 (91–98.32) 71.68 (64.34–78.25)
False discovery rate (%) 0 5.34 28.32
Negative predictive value (%), (95% CI) 31.17 41.29 (37.47–45.11) 40.45 (30.17–51.38)
False omission rate (%) 68.83 58.71 59.55
Area under the ROC curve, (95% CI) 0.98 (0.96–1) 0.86 (0.82–0.91) 0.60 (0.51–0.67)
Abbreviations: DHCR24, 3β-hydroxysterol Δ24-reductase antibody; HCV, hepatitis C virus; HCC-C, HCV-related hepatocellular carcinoma; CHC, HCV-related chronic hepatitis; LCC, HCV-
related liver cirrhosis; CI, conﬁdence interval; ROC, receiver operating characteristics.
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3.1. Setup of ELISA
We recruited 651 participants from September 2007 to November
2014 (Fig. 1). The main clinical and demographic characteristics of the
study population are summarized in Table 1. We screened the DHCR24
Ab levels in the patient sera using ELISA. The antigen for ELISA was
puriﬁed fromHuH-7 cells (Fig. 2), as the recombinant DHCR24 expressed
in E. coli did not show proper reactivity (data not shown). The concentra-
tion of DHCR24 Ab levels was determined usingmouse anti-DHCR24 as a
standard. The dose-response relationship between DHCR24 Ab concen-
tration and optical density was very good (range, 0–2 μg/mL), and the
lowest detectable concentration was 0.05 μg/mL.(A)  
(C)  
Fig. 4. The performance of serummarkers in the discrimination between hepatitis C virus-relat
sults for combinations of PIVKA-II, AFP, andDHCR24Ab in patientswith HCC-C. (B) Performance
among healthy, chronic hepatitis C, LCC, and early and late HCC-C patients. AUC, area under th3.2. DHCR24 Ab Levels in HCV-infected Patients
The concentration of DHCR24 Ab was signiﬁcantly higher in CHC
patients compared to in healthy subjects (P b 0.0001), but signiﬁcantly
lower compared to in HCC-C patients (P b 0.0001) in all hospitals
(Fig. 3A, B, C, Supplementary Fig. 1). Overall, the DHCR24 Ab level was
signiﬁcantly higher in HCC-C patients (mean: 16.46 ± 0.63 μg/mL)
compared to CHC (8.69 ± 0.25 μg/mL, P b 0.0001) and LCC (13.82 ±
0.81 μg/mL, P = 0.0418) patients and healthy controls (4.75 ±
0.51 μg/mL, P b 0.0001; Fig. 3C). One-way ANOVA revealed signiﬁcant
differences between HCC-C and LCC and CHC patients (P b 0.0001).
ROC curves were plotted to identify the optimal cutoff values to
distinguish HCC from HCV chronic carriers (Supplementary Fig. 2).
The sensitivity and speciﬁcity of serum DHCR24 Ab for the diagnosis(B)  
ed hepatocellular carcinoma (HCC-C) and chronic hepatitis (CHC). (A) Rates of positive re-
of DHCR24AB in PIVKAII-negative and AFP-negative cases. (C) Serum levels of DHCR24Ab
e curve; CI, conﬁdence interval.
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76.88–89.95%), respectively (cutoff, 11.5 μg/mL). The corresponding
values for AFP were 53.49% (95% CI: 45.74–61.12%) and 97.66% (95%
CI: 93.30–99.51%), respectively (cutoff, 20 ng/mL), and those of
PIVKA-II Ab were 42.51% (95% CI: 34.91–50.39%) and 100% (95% CI:
96.38–100%), respectively (cutoff, 40 mIU/mL). Additionally, a compre-
hensive assessment of the diagnostic accuracy of DHCR24 Ab was
performed for HCC-C (Table 2).
DHCR24 Ab showed an AUC of 0.86 (95% CI: 0.82–0.91) in
distinguishing HCC-C from CHC patients, which was compared with
AFP (0.84, 95% CI: 0.82–0.91) and PIVKA-II (0.78, 95% CI: 0.73–0.84)
(Supplementary Fig. 2). A greater proportion of patients with HCC-C
were positive for DHCR24 Ab (125/177, 71%) than for AFP (93/172,
54%) and PIVKA-II (73/167, 44%) (P b 0.0001; Fig. 4A). Combined
serum DHCR24 Ab and PIVKA-II or AFP levels increased the positive
rates of HCC cases to 87% and 88%, respectively (Fig. 4A). Furthermore,
46% (79/172) of patients were considered AFP-negative (b20 ng/mL).
Among them, the serum DHCR24 Ab levels were elevated in 73.4%
(58/79) (Fig. 4B). Moreover, 56.3% (94/167) were considered PIVKA-
II-negative (b40 mIU/mL). Among them, the serum DHCR24 Ab levels
were elevated in 75.5% (71/94) (Fig. 4B). Additionally, DHCR24
Ab could signiﬁcantly differentiate between early HCC and cirrhosis(A) Komagome Hospital
(C) Total
Fig. 5. Serum levels of DHCR24 Ab in hepatitis B virus (HBV)-infected patients with chronic hep
DHCR24 Ab in hepatitis B patients and healthy controls in (A) Komagome Hospital and (B) Kan
controls (all hospitals). Black horizontal lines indicate means and error bars indicate standard d
HCC-B, hepatocellular carcinoma with HBV infection.(P = 0.0306) and early HCC-and late HCC (P = 0.0142) in chronic
hepatitis C patients (Fig. 4C).
We further evaluated the performance of DHCR24Ab in discriminat-
ing CHC vs. LCC; ROC curves showed an AUC of 0.74 (95% CI: 0.66–0.83),
which was similar to that of AFP (0.68, 95% CI: 0.66–0.77) and
signiﬁcantly better than that of PIVKA-II (0.56, 95% CI: 0.43–0.62)
(Supplementary Fig. 3).
Spearman correlation analyses between DHCR24 Ab and AFP
or PIVKA-II levels showed no clear correlations (rs = −0.15, 95%
CI: −0.30–0.01, P = 0.0668, R2 = 0.0076; and rs = 0.08, 95% CI:
0.24–0.083, P = 0.3149, R2 = 0.0161, respectively (Supplementary
Fig. 4).
3.3. DHCR24 Ab Levels in HBV-infected Patients
Next, we investigated the serum levels of DHCR24 Ab from patients
with CHB, LCB, and HCC-B (Fig. 5, Supplementary Fig. 5). Stratiﬁcation
analysis by hospital showed that the DHCR24 Ab levels were higher in
CHB patients compared to in healthy controls (Fig. 5A–C). Overall, the
concentration of DHCR24 Ab in HCC-B (mean: 7.16 ± 0.50 μg/mL)
showed no signiﬁcant differences compared to CHB (6.49 ±
0.37 μg/mL) and LCB patients (7.87 ± 0.60 μg/mL) (P = 0.1247).(B) Kanazawa Hospital
atitis, liver cirrhosis, and hepatocellular carcinoma, and in healthy controls. Serum levels of
azawa hospital. (C) Plotted serum levels of DHCR24 Ab in hepatitis B patients and healthy
eviations. CHB, chronic hepatitis B virus infection; LCB, liver cirrhosis with HBV infection;
610 S. Ezzikouri et al. / EBioMedicine 2 (2015) 604–612However, it was signiﬁcantly higher in patients with chronic hepatitis B
(CHB, LCB, or HCC-B) than in healthy controls (P b 0.05) (Fig. 5C). The
AUC for distinguishing between HCC-B and CHB for DHCR24 Ab (0.50,
95% CI: 0.41–0.60) was not superior to that of PIVKA-II (0.73, 95% CI:
0.64–0.82) or AFP (0.77, 95% CI: 0.71–0.83) (Supplementary Fig. 6),
indicating that DHCR24 Ab is not a good biomarker for HCC-B.
3.4. DHCR24 is Differentially Expressed in Liver Cancer Tissues
To determine whether HCV infection induces DHCR24 protein
expression in HCC, 15 primary human HCC tissues and adjacent non-
tumor tissues were subjected to Western blot analysis using DHCR24
monoclonal antibody 2-152a. DHCR24 was overexpressed in all HCV-
positive tumor tissues compared to the adjacent non-tumor tissues
(Fig. 6A), as well as in two out of ﬁve HBV-related, or HBV-negative,
HCV-negative HCC specimens (Fig. 6A). Furthermore, immunohisto-
chemical analyses revealed that the DHCR24 protein expression was
increased in cancerous HCV-tissues (Fig. 6B) and reduced in cancerous
HBV-positive (Fig. 5C) and HBV-negative, HCV-negative-tissues
(Fig. 6D). Taken together, these data indicate that DHCR24 is more fre-
quently up-regulated in HCV-cancerous than in HBV-cancerous tissues.
3.5. Relationship Between DHCR24 Ab Levels and Clinicopathologic
Features in HCC-C Patients
Solitary HCC is thought to be de novo occurrence and multiple HCC
includes de novo and intrahepatic metastases. We compared the
DHCR24 Ab levels between in solitary HCC-C and multiples HCC. In
fact, the concentration of DHCR24 Ab was signiﬁcantly higher among
patients with multiple HCC (18.15 ± 1.15 μg/mL) than in those with
solitary HCC (15.07 ± 0.81 μg/mL) (P = 0.0417; Fig. 7A). Moreover,
the DHCR24 Ab levels were compared before and after treatment in
patients who underwent transcatheter arterial chemoembolization for
HCC (n = 8). However, the DHCR24 Ab levels did not differ before
and after the treatment (P = 0.5664; Fig. 7B).Fig. 6. The DHCR24 expression is up-regulated in hepatitis C virus (HCV)-tumor tissues, and a
chemoembolization (TACE). (A) Western blot showing DHCR24 expression in cancerous an
were infected with HCV (HCV+), ﬁve were infected with hepatitis B virus (HBV+), and ﬁve w
of (B) HCV-infected cancerous tissues, (C) HBV-infected cancerous tissues, and (D) NBNC tissu
the 2-152a monoclonal Ab. Topro-3 was used for counterstaining of the nuclei. HE, hematoxyl4. Discussion
In the serum, Abs are stable and the Ab response is enduring (Heo
et al., 2012), and overexpressed, mutated, misfolded, or aberrantly de-
graded proteins can become immunogenic, thus resulting in auto-Ab
production; consequently, the detection of these antibodies in patient
sera can be exploited for prognostic and/or diagnostic purposes.
In this study, we found that serumDHCR24Ab levels correlatedwith
HCV-mediated chronic hepatitis, cirrhosis, and HCC, but not with HBV-
related diseases, suggesting that the concentration of serum DHCR24
Abs may be useful for the diagnosis and/or prognosis in HCV-positive
patients. Moreover, the sensitivity of the DHCR24 Ab in discriminating
CHC from HCC-C patients was superior to serum AFP and PIVKA-II
levels, and high DHCR24 Ab levels demonstrated a high positive predic-
tive value for HCC-C. Additionally, a combination of DHCR24 Ab with
AFP or PIVKA-II further increased the detection rates of HCC in HCV-
positive patients. Conversely, in chronic HBV infection, the DHCR24 Ab
levels did not differ between CHB, LCB, and HCC-B (P = 0.1247).
Previously, we have shown that DHCR24 is overexpressed in HCV-
infected cells in vitro and in vivo, and that HCV silencing by siRNA
down-regulated DHCR24 expression (Nishimura et al., 2009; Saito
et al., 2012; Takano et al., 2011). However, HBV infection had no
signiﬁcant effect on DHCR24 expression (Makuuchi et al., 2008).
DHCR24 up-regulation in HCV infection may be due to increased Sp1
phosphorylation by ataxia telangiectasia mutated as a result of
HCV-induced oxidative stress, which promotes transcriptional activa-
tion of DHCR24 (Tsukiyama-Kohara, 2012). Thus, chronic HCV infection
could induce the augmentation of DHCR24. Also, this augmentation of
DHCR24 expression by HCV suppresses p53 activity by blocking nuclear
p53 acetylation and increasing the interaction between p53 andMDM2
in the cytoplasm, potentially mediated by inhibition of p53 degradation
(Tsukiyama-Kohara, 2012). Consequently, impaired apoptotic signaling
upon p53 activity suppression may facilitate hepatocarcinogenesis.
Moreover, DHCR24 has been shown to inhibit caspase-3 activation,
one of the major proteins involved in apoptosis, suggesting a role of
DHCR24 in the regulation of cell survival and death (Greeve et al.,ssociation between DHCR24 Ab levels with tumor progression, and transcatheter arterial
d non-cancerous regions in the livers of 10 hepatocellular (HCC) patients. Five patients
ere not infected with HBV and HCV (NBNC). Immunoﬂuorescence and histological images
es obtained using immunohistochemistry. DHCR24 protein expression was detected using
in and eosin.
(A) (B)
Fig. 7.Association between 3β-hydroxysterolΔ24-reductase antibody (DHCR24Ab) levelswith tumor progression, and transcatheter arterial chemoembolization (TACE). (A) DHCR24 Ab
level comparison ` solitary HCC andmultipleHCCs in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC-C) patients. (B) Changes in theDHCR24 levels before and after TACEof
HCC-C patients.
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2-152a clone can bind DHCR24 and suppress HCV replication (Satoh
et al., 2011), suggesting that the DHCR24 Ab has antiviral effects, and
that high levels of DHCR24 Ab in HCC patients may lead to lower HCV
RNA levels in the cancerous tissues. DHCR24 is reportedly more
abundantly expressed on the surface of liver cancer cells than normal
hepatocytes Satoh et al., 2011. Accordingly, Tanaka et al. observed that
non-cancerous tissues of patients with HCC and HCV mono-infection
displayed virus levels 10- to 1000-fold higher than cancerous tissues,
and this may be one of the reasons for the higher amount of DHCR24
Ab seen in HCC patients (Tanaka et al., 2004).
The DHCR24 gene has been mapped to chromosome 1p32.3, a
region commonly ampliﬁed in HCC and which may contribute to carci-
nogenesis (Yuan et al., 2003; Endo et al., 2009). Recently, two somatic
mutations, Q88L and R311H, were identiﬁed in the DHCR24 gene in Ko-
reanHCC patients (Ahn et al., 2014). Further, overexpression of DHCR24
is a hallmark of prostate cancer, with high levels observed in low-grade
prostate cancer, but diminishing as the cancer progresses (Bonaccorsi
et al., 2008), and it is also overexpressed during non-muscle-invasive
urothelial carcinoma progression (Lee et al., 2014).
In conclusion, DHCR24 Ab levels might represent a novel marker for
advanced liver disease. The increase in DHCR24 Abs from moderate
chronic hepatitis to advanced-stage disease provides a potential novel
diagnostic system for early-stage disease progression and suggests
that serum DHCR24 Ab elevation may reﬂect the progression of
autoimmunity-related inﬂammation to HCC in HCV-positive patients.
However, further studies are required to clarify the mechanism of
serum DHCR24 Ab induction during chronic HCV infection.
5. Conclusions
A thorough Medline and PubMed search without date restrictions,
for original research articles, using the search terms “DHCR24 antibody
OR Seladin-1 antibody AND (cancer OR tumor OR neoplasm) AND
diagnosis”, and “DHCR24 Ab OR Seladin-1 Ab AND (hepatocellular
carcinoma OR liver cancer)”. However, we found no studies that
had assessed the diagnostic relevance of serum 3β-hydroxysterol
Δ24-reductase antibody (DHCR24 Ab) in hepatocellular carcinoma
(HCC) or other human cancers.
Herein, for the ﬁrst time, we measured and comprehensively
assessed the diagnostic accuracy of DHCR24 Ab in HCC in a large-scale,
multicenter investigation. The DHCR24 Ab level was found to be in-
creased during hepatitis C virus (HCV) infection disease progression.
The sensitivity and speciﬁcity of the DHCR24 Ab were high, and the
predictive values and likelihood ratios were satisfactory for the
diagnosis of HCV-related-HCC and in patients with alpha-fetoprotein(AFP)-negative or protein induced by vitamin K absence or antagonist-II
(PIVKA-II)-negative status. Therefore, measurement of DHCR24 Ab in
the serum may facilitate the diagnosis of PIVKA-II and AFP-negative
HCC and improve the detection rate of HCC-C. However, the test could
not distinguish hepatitis B virus (HBV)-related-HCC from HBV-related
chronic hepatitis or liver cirrhosis, and we found that DHCR24 was
up-regulated in HCV-positive, but not HBV-positive, tissues.
Our data indicate that the DHCR24 Ab shows potential as a prognostic
factor for HCV chronic infection and reﬂect the autoimmune response,
and should be investigated further.Conﬂicts of Interest
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